Marubi(SH:603983)2024-04-26 11:35Financial Performance - The total cost for the personal care segment was CNY 651,841,811.49, representing a 19.44% increase compared to CNY 545,763,947.39 in the previous year[2]. - The company reported a significant increase of 464.74% in cash received from investment income, totaling CNY 30,657,008.10 compared to CNY 5,428,512.94 in the previous year[4]. - The company experienced a 50.69% increase in cash payments related to operating activities, totaling CNY 982,984,677.09 compared to CNY 652,329,796.62 last year[4]. - The net profit attributable to shareholders for the fourth quarter was CNY 85,589,793.23, showing a significant increase compared to previous quarters[34]. - The company's net assets attributable to shareholders increased by 4.99% year-on-year, totaling CNY 3,347,129,838.58[31]. - Revenue for the fourth quarter was CNY 689,154,384.11, contributing to a total annual revenue growth driven by increased sales[34]. - The company reported a total net profit of approximately 71.58 million, with a significant increase in non-recurring gains and losses amounting to 33.99 million[37]. - The company's operating revenue for 2023 reached ¥2,225,594,089.54, representing a year-on-year increase of 28.52% compared to ¥1,731,716,457.94 in 2022[54]. - Net profit attributable to shareholders for 2023 was ¥259,417,875.91, a 48.93% increase from ¥174,183,372.68 in 2022[54]. - The net profit after deducting non-recurring gains and losses for 2023 was ¥187,834,455.27, reflecting a 38.16% increase from ¥135,950,751.96 in 2022[54]. Cost and Expenses - The raw material costs for the skincare product line amounted to CNY 194,345,926.80, which is a 7.70% increase from CNY 180,445,783.74 last year[2]. - The company reported a 43.28% increase in external purchase costs in the personal care segment, totaling CNY 52,870,509.76 compared to CNY 36,898,952.66 last year[2]. - Cash payments for the construction of fixed assets increased by 129.06%, amounting to CNY 254,045,488.15, due to higher investments in the headquarters building[4]. - Sales expenses increased by 41.65% to 1.199 billion yuan, while management expenses decreased by 2.14% to 109 million yuan[82]. - R&D expenses increased by 17.69% to approximately ¥62.29 million, reflecting the company's commitment to innovation[74]. Sales and Market Performance - The top five customers contributed CNY 32,480.26 million in sales, accounting for 14.59% of the total annual sales[7]. - The company achieved a gross merchandise volume (GMV) sales of over ¥200 million for the Marubi Eye Cream, ranking as the top domestic eye cream on multiple platforms[66]. - The Marubi Double Collagen Essence also achieved GMV sales exceeding ¥200 million, enhancing brand recognition in biotechnology and anti-aging[66]. - The main brand, Marubi, generated 1.56 billion yuan in revenue, accounting for 70.14% of total revenue, with a year-on-year growth of 11.63%[82]. - The PL brand, Lianhuo, saw a significant revenue increase of 125.14%, reaching 643 million yuan, contributing 28.92% to total revenue[82]. - The company's online sales model generated approximately ¥1.87 billion, accounting for a 50.40% increase compared to the previous year[76]. - Online sales accounted for 84.11% of total revenue, reaching 1.871 billion yuan, with a year-on-year growth of 50.40%[86]. - Direct sales made up 68.25% of total revenue, indicating a fundamental shift in the sales model towards online and direct sales[86]. Research and Development - The company has developed over 50 self-researched raw materials, with more than 30 using green innovative plant extraction technology[42]. - The company has applied for a total of 510 patents, including 400 invention patents, and has published 35 papers, with a cumulative impact factor of 17.12[43]. - The company established a new production line for innovative plant extraction, enhancing the conversion of research results into products[43]. - The company has formed partnerships with over 20 domestic and international research institutions to enhance its R&D capabilities[43]. - The number of R&D personnel is 93, accounting for 8.45% of the total workforce[113]. - The R&D personnel structure includes 7 PhDs, 20 Master's, 44 Bachelor's, and 22 Associate degrees[113]. Financial Position and Assets - Total assets at the end of 2023 reached CNY 4,453,746,770.48, representing an 8.78% increase from the previous year[31]. - The weighted average return on net assets increased to 7.94% in 2023, up by 2.38 percentage points from 5.56% in 2022[56]. - The company's financial assets measured at fair value and recognized in profit or loss increased to ¥767,976,164.16 from ¥437,776,231.46, representing a growth of approximately 75.5%[174]. - The company's investment in financial products rose to ¥376,049,067.59 from ¥135,301,225.46, marking an increase of approximately 177.5%[174]. - The corporate income tax rate for the main subsidiaries is set at 15% for Guangdong Marubi Biotechnology Co., Ltd. and Chongqing Bodo Logistics Co., Ltd.[171]. Operational Efficiency - The company achieved a 15% increase in production efficiency and an average delivery cycle of 43.3 days during the year[46]. - Daily chemical product production reached 46,572,198 units, with sales of 38,560,163 units, reflecting a production increase of 45.99% and a sales increase of 31.32% year-over-year[117]. - The company has established a comprehensive supply chain system to ensure material quality and operational efficiency[71]. - The company streamlined its organizational structure to enhance flexibility and responsiveness to market changes[69]. Risk Management and Compliance - The company emphasizes the importance of risk awareness regarding forward-looking statements made in the report[22]. - The company has provided a standard unqualified audit report from Huaxing Accounting Firm[13]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[14]. - The company has not recognized any significant recoveries or reversals of bad debt provisions during the reporting period[162]. - The company has not disclosed any significant changes in the financing of receivables during the reporting period[165].